Thryve Peptides
CJC-1295 with DAC (5mg)
CJC-1295 with DAC (5mg)
Couldn't load pickup availability
CJC-1295 with DAC 5MG
Long-acting GHRH analog engineered for research precision and stability.
- CJC-1295 with DAC (Drug Affinity Complex) is a synthetic peptide designed to extend the biological half-life of GHRH analogs in research environments.
- Formulated to support studies on growth hormone (GH) pulsatility, IGF-1 modulation, and endocrine peptide signaling.
- Independently verified by Vanguard Laboratory for purity, composition, and sequence accuracy.
For laboratory research use only. Not for human consumption.
Scientific Evidence
CJC-1295 with DAC incorporates a Drug Affinity Complex that allows reversible albumin binding, significantly extending peptide half-life and enhancing receptor engagement (PubMed 16507602).
Studies indicate sustained elevation of GH and IGF-1 levels lasting up to six days post-administration in controlled test subjects (PubMed 16492960).
This long-acting design allows researchers to explore endocrine modulation and peptide pharmacokinetics under extended exposure models (PubMed 20930154).
Regulatory Status: CJC-1295 with DAC is not FDA-approved for human or veterinary use and is provided exclusively for research purposes.
